Literature DB >> 3661438

Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension.

D R Abernethy1, J B Schwartz, J R Plachetka, E L Todd, J M Egan.   

Abstract

Pharmacodynamics and pharmacokinetics of labetalol, a combined alpha- and beta-adrenoceptor antagonist drug, were studied in elderly and young hypertensive patients. After receiving intravenous labetalol, elderly patients had a greater maximal mean decrease in systolic blood pressure (BP) (39 +/- 8 vs 25 +/- 13 mm Hg, p less than 0.02); however, maximal decrease in diastolic BP was similar in elderly (18 +/- 10 mm Hg) and young (17 +/- 6 mm Hg) patients. After receiving oral labetalol, elderly patients had a greater maximal decrease in standing systolic BP (41 +/- 16 vs 16 +/- 14 mm Hg, p less than 0.001) and similar decreases in standing diastolic BP (21 +/- 7 vs 17 +/- 9 mm Hg). Sitting maximal BP decreases after oral labetalol treatment were similar in elderly and young patients (12 +/- 16 vs 17 +/- 7 mm Hg systolic and 24 +/- 6 vs 12 +/- 7 diastolic). The decrease in heart rate was greater in young patients after intravenous labetalol administration. To evaluate labetalol pharmacodynamics, a linear model was used. Slope of labetalol concentration vs systolic BP for elderly vs young patients was 0.928 +/- 1.05 vs 0.326 +/- 0.490 ng/ml X mm Hg-1 (difference not significant). The slope of labetalol concentration vs heart rate for elderly vs young patients was 0.176 +/- 0.063 vs 0.406 +/- 0.303 ng/ml X beats/min-1 (p less than 0.05), with 2 elderly patients showing no decrease in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3661438     DOI: 10.1016/0002-9149(87)90385-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  [Pharmacotherapy of elderly patients].

Authors:  H Burkhardt; M Wehling; R Gladisch
Journal:  Internist (Berl)       Date:  2007-11       Impact factor: 0.743

Review 4.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 5.  Drug-induced orthostatic hypotension in the elderly: avoiding its onset.

Authors:  I Verhaeverbeke; T Mets
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

6.  Effects of age on the elimination of labetalol.

Authors:  M L Rocci; T Valiquett; M A Sirgo
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 7.  [Prevention of adverse drug reactions in older patients].

Authors:  H Burkhardt; M Wehling; R Gladisch
Journal:  Z Gerontol Geriatr       Date:  2007-08       Impact factor: 1.281

Review 8.  Free drug metabolic clearance in elderly people.

Authors:  Jennifer M Butler; Evan J Begg
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  Drug-induced orthostatic hypotension in older patients.

Authors:  T F Mets
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 10.  Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.

Authors:  Miranda R Andrus; Joyce V Loyed
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.